Literature DB >> 7525617

Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis.

M S Pepper1, J D Vassalli, J W Wilks, L Schweigerer, L Orci, R Montesano.   

Abstract

A tightly controlled increase in extracellular proteolysis, restricted both in time and space, is an important component of the angiogenic process, while anti-proteolysis is effective in inhibiting angiogenesis. By focussing on the plasminogen activator (PA)-plasmin system, the objective of the present studies was to assess whether previously described inhibitors of angiogenesis modify bovine microvascular endothelial cell proteolytic properties. We demonstrate that although synthetic angiostatic steroids (U-24067 and U-42129), heparin, suramin, interferon alpha-2a, and retinoic acid are all inhibitors of in vitro angiogenesis, each of these agents has distinct effects on the plasminogen-dependent proteolytic system. Specifically, angiostatic steroids and interferon alpha-2a reduce urokinase-type PA (u-PA) and PA inhibitor-1 activity, while heparin and retinoic acid increase u-PA activity. Suramin reduces cell-associated u-PA activity and greatly increases PAI-1 production at doses which induce monolayer disruption. These findings demonstrate that a spectrum of alterations in extracellular proteolysis is associated with anti-angiogenesis, and that anti-angiogenesis and anti-proteolysis are not necessarily correlated. A reduction in extracellular proteolysis would be expected to reduce invasion, whereas an increase in proteolysis might modulate the activity of inhibitory cytokines, which in turn could reduce endothelial cell proliferation and migration and inhibit angiogenesis. The spectrum of effects on different elements of the PA system observed in response to the agents assessed suggests that the role of modulations in extracellular proteolytic activity in anti-angiogenesis is likely to be varied and complex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525617     DOI: 10.1002/jcb.240550403

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter.

Authors:  J Bian; Y Sun
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 3.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

4.  Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.

Authors:  Z Szekanecz; G K Haines; A E Koch
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 5.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

Review 6.  New concepts in fibrinolysis and angiogenesis.

Authors:  K A Hajjar; A Deora
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

7.  Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

8.  Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization.

Authors:  Yanhui Bai; Weiqun Wang; Guangli Sun; Mingchang Zhang; Jingmin Dong
Journal:  Cell Prolif       Date:  2016-09-14       Impact factor: 6.831

9.  Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Authors:  Gretchen A Larusch; Alona Merkulova; Fakhri Mahdi; Zia Shariat-Madar; Robert G Sitrin; Douglas B Cines; Alvin H Schmaier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.